Liquidia CORP 8-K filings

Liquidia Corporation announced robust second quarter 2026 financial results, highlighted by a 31% sequential increase in YUTREPIA net product sales to $170.4 million and a fourth consecutive quarter of increasing profitability.

Liquidia Corporation announced the results of its annual meeting of stockholders held on June 16, 2026, including the election of directors and ratification of its accounting firm.

Liquidia Corporation announced its inclusion in the S&P SmallCap 600 Index, effective June 22, 2026, reflecting its growth and market position.

Liquidia Corporation announced robust first quarter 2026 financial results, showcasing significant net product sales for YUTREPIA and achieving its third consecutive quarter of profitability.

Liquidia Corporation announced robust full-year 2025 financial results, driven by strong YUTREPIA sales and achieving its second consecutive quarter of profitability.

Liquidia Corporation announced preliminary full-year 2025 YUTREPIA net sales of $148.3 million and positive Q4 cash flow, signaling strong commercial momentum.

Liquidia Corporation reported strong third-quarter 2025 financial results, achieving profitability with $51.7 million in YUTREPIA net product sales and positive adjusted EBITDA.

Liquidia Corporation's subsidiary entered an exclusive licensing agreement with Vectura Limited for L606 in the U.S., targeting hypertension and interstitial lung diseases.

Liquidia Corporation announced robust initial sales for its newly approved YUTREPIA, alongside positive clinical trial data, despite an increased net loss in the second quarter of 2025.

Liquidia Corporation announced the appointment of Dana Boyle as its new Chief Accounting Officer, effective July 1, 2025, along with her compensation and severance arrangements.

Liquidia Corporation announced the receipt of an additional $50.0 million from HealthCare Royalty Partners, triggered by the first commercial sale of YUTREPIA and the denial of a preliminary injunction against the company.

Liquidia Corporation announced the successful election of three Class I directors, the ratification of PricewaterhouseCoopers LLP as its independent auditor, and the advisory approval of executive compensation at its annual meeting held on June 17, 2025.

Liquidia Corporation's subsidiary, Liquidia Technologies, Inc., has entered into a new long-term lease agreement for a 70,131 square foot manufacturing facility in Morrisville, North Carolina.

Liquidia Corporation announced that a U.S. District Court denied United Therapeutics' motion for a preliminary injunction, clearing the path for the immediate commercial launch and first shipment of its FDA-approved YUTREPIA (treprostinil) inhalation powder for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

Liquidia Corporation announced today that its YUTREPIA (treprostinil) inhalation powder has received final U.S. FDA approval for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), following the expiration of United Therapeutics' Tyvaso DPI exclusivity.

Liquidia Corporation is facing a lawsuit from United Therapeutics Corporation alleging infringement of a patent related to YUTREPIA, Liquidia's investigational drug for pulmonary hypertension.

Liquidia Corporation announced its Q1 2025 financial results, highlighted by awaiting FDA action on YUTREPIA, dismissal of a cross-claim by United Therapeutics, full enrollment of Cohort A in the ASCENT study, and strengthened financial position via access of up to $100 million from an existing financing agreement.

Liquidia Corporation voluntarily files a Form 8-K to revise previously issued financial statements due to immaterial accounting errors related to the treatment of amendments to a revenue interest financing agreement.

Liquidia Corporation announces a favorable court decision dismissing United Therapeutics' challenge to its New Drug Application (NDA) amendment for YUTREPIA, potentially paving the way for FDA approval.

Liquidia Corporation's subsidiary, Liquidia Technologies, Inc., has initiated a patent infringement lawsuit against United Therapeutics Corporation regarding U.S. Patent No. 10,898,494 related to dry powder treprostinil for pulmonary hypertension treatment.

The FDA has accepted Liquidia's resubmitted New Drug Application for YUTREPIA, setting a PDUFA goal date for potential approval.

Liquidia Corporation reports its full year 2024 financial results, highlights progress towards potential YUTREPIA approval, and secures additional financing.

Liquidia Corporation has amended its agreement with HealthCare Royalty to potentially receive up to $100 million in additional funding to support the commercial development of YUTREPIA and other clinical programs.

Liquidia Corporation's lawsuit challenging the FDA's decision to grant regulatory exclusivity to United Therapeutics' Tyvaso DPI was unsuccessful, as the District Court ruled in favor of the FDA and United Therapeutics.

Liquidia Corporation's subsidiary, Liquidia Technologies, Inc., has extended its headquarters lease in Durham, North Carolina, for an additional 62 months, securing its location through December 2031 and gaining a right of first offer on vacant space in the building.

Liquidia Corporation reported its third quarter 2024 financial results, highlighted by a tentative FDA approval for YUTREPIA and a strengthened balance sheet through a $100 million capital raise.

The U.S. Supreme Court has rejected United Therapeutics' appeal, finalizing rulings that invalidate a key patent and paving the way for Liquidia's YUTREPIA launch.

Liquidia Corporation has broadened its licensing agreement with Pharmosa Biopharm to include key European and Japanese markets for its inhaled treprostinil treatment, L606, and secured rights to next-generation nebulizer technology.

Liquidia Corporation is facing new cross-claims from United Therapeutics in an ongoing lawsuit regarding the FDA's acceptance of Liquidia's New Drug Application for YUTREPIA.

Liquidia Corporation successfully closed a public offering and a private placement, raising a total of $67.5 million, and secured an additional $32.5 million in funding from Healthcare Royalty Partners.